---
type: "Topics"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/topics/36002994.md"
description: "$XTALPI(02228.HK) Just curious, will the transformation and upgrading of AI in various industries become a meaningless false proposition, except for pharmaceuticals, which inherently require enumeration and testing due to their high uncertainty."
datetime: "2025-11-05T02:08:01.000Z"
locales:
  - [en](https://longbridge.com/en/topics/36002994.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/36002994.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/36002994.md)
author: "[见好就收688](https://longbridge.com/zh-CN/profiles/15782830.md)"
---

> 支持的语言: [English](https://longbridge.com/en/topics/36002994.md) | [繁體中文](https://longbridge.com/zh-HK/topics/36002994.md)


# $XTALPI(02228.HK) Just curious, will the transform…


### 相关股票

- [XTALPI (02228.HK)](https://longbridge.com/zh-CN/quote/02228.HK.md)

## 评论 (3)

- **John_Tang · 2025-11-05T03:25:24.000Z**: But at least Jintai is in the CRO model in the pharmaceutical field, which carries much less risk compared to pure drug research companies.
- **啊这样子吗 · 2025-11-05T02:29:45.000Z**: Although AI has certain advantages in developing new drugs, being able to calculate which structures are more likely to yield results and save time and money, it ultimately cannot bypass current cognitive limitations—it merely improves upon the original brute-force method.
- **周树人的交易员 · 2025-11-05T02:15:38.000Z**: This idea is absolutely correct, it's a high-stakes gamble from the start